Attached files
file | filename |
---|---|
EX-99.1 - ADDITIONAL EXHIBITS - Bionik Laboratories Corp. | bionik-marcummicrocapfina.htm |
UNITED STATES
|
SECURITIES AND EXCHANGE COMMISSION
|
WASHINGTON, DC 20549
|
|
FORM 8-K
|
CURRENT REPORT PURSUANT
|
TO SECTION 13 OR 15(D) OF THE
|
SECURITIES EXCHANGE ACT OF 1934
|
|
Date of
report (Date of earliest event reported): June 6, 2017
|
BIONIK
LABORATORIES CORP.
|
(Exact
Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
000-54717
|
|
27-1340346
|
(State
or Other Jurisdiction of Incorporation or
Organization)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
483 Bay Street, N105
Toronto, ON
|
|
M5G 2C9
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (416) 640-7887
|
||
|
||
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
|
Emerging
growth company ☐
|
|
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01
|
Regulation FD Disclosure
|
On June
6, 2017, Bionik Laboratories Corp. (the “Registrant”)
issued a press release announcing that Peter Bloch, its Chief
Executive Officer, will present at the 6th Annual 2017 Marcum
MicroCap Conference on Friday, June 16, 2017 at 11:00 am ET. The
conference will be held at The Grand Hyatt Hotel in New York
City.
During
his presentation, Mr. Bloch will provide a corporate update and
discuss the Registrant’s propriety assistive robotic therapy
systems that are commercially available for treatment of stroke and
other neurological disorders, as well as new products currently
under development.
A copy
of the press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference. The
information in this report (including Exhibit 99.1) is being
furnished pursuant to Item 7.01 and shall not be deemed to be
“filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section. This report will not be deemed
an admission as to the materiality of any information herein
(including Exhibit 99.1).
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
Exhibit
|
|
Description
|
99.1
|
|
Press Release
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: June 6, 2017
|
BIONIK LABORATORIES CORP.
|
|
|
|
|
|
By:
|
/s/
Leslie
Markow
|
|
Name:
|
Leslie
Markow
|
|
Title:
|
Chief
Financial Officer
|